Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Soiken Holdings's Revenue for the
three
months ended in Mar. 2026 was 円822 Mil. Soiken Holdings's average Accounts Receivable for the
three
months ended in Mar. 2026 was 円247 Mil.
Hence, Soiken Holdings's Receivables Turnover for the
three
months ended in Mar. 2026 was 3.33.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Soiken Holdings Receivables Turnover Related Terms
Soiken Holdings Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Soiken Holdings's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2385 vs VRTX, REGN, MRNA: Receivables Turnover Comparison
For the Biotechnology subindustry, Soiken Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Soiken Holdings Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Soiken Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Soiken Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Soiken Holdings (TSE:2385) has a Receivables Turnover of 3.33 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Soiken Holdings and its competitors. According to the industry distribution chart, Soiken Holdings ranks #114 out of 853 companies in the Biotechnology industry, placing it in the top 13.4%.
Is Soiken Holdings' Receivables Turnover too high?
Soiken Holdings' current Receivables Turnover is 3.33. The Biotechnology industry median Receivables Turnover is 5.28. Soiken Holdings' value of 3.33 is 36.9% below this industry median. Based on the distribution chart, Soiken Holdings ranks #114 out of 853 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Soiken Holdings has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Soiken Holdings' Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Soiken Holdings ranks #114 out of 853 companies for Receivables Turnover. This places Soiken Holdings in the top 13% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.28. Soiken Holdings' value of 3.33 is 36.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Soiken Holdings's current Receivables Turnover of 3.33 is 36.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Soiken Holdings and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Soiken Holdings's current Receivables Turnover is 3.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Soiken Holdings stock overvalued right now?
Based on GuruFocus' analysis, Soiken Holdings (TSE:2385) is currently considered Significantly Overvalued. The stock's GF Value™ is 円111.04, compared to a current price of 円218.00 — trading 96.3% above its estimated fair value. The current Receivables Turnover is 3.33 and 36.9% below the Biotechnology industry median of 5.28. Soiken Holdings' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Soiken Holdings (TSE:2385), the current Receivables Turnover is 3.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Soiken Holdings (TSE:2385) Overvalued in 2026?
Based on GuruFocus' analysis, Soiken Holdings stock appears to be overvalued.
The current stock price of 円218.00 is trading 96.3% above its estimated GF Value™ of 円111.04.
GuruFocus considers Soiken Holdings to be Significantly Overvalued.
Key valuation signals for TSE:2385:
Receivables Turnover: 3.33
GF Value™: 円111.04 vs. price of 円218.00 (96.3% above fair value)
Industry Position: 36.9% below the Biotechnology median (#114 of 853)
No single metric tells the full story. See the TSE:2385 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Soiken Holdings Inc operates as a biotechnology company in Japan. It provides clinical testing for pharmaceutical and food manufacturers that develop drugs and health food products based on biomarkers. It is involved in the marketing research and post-marketing surveillance of health supplements.
55GF Score
Get the complete analysis for TSE:2385
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2385 has been successfully added to your 
